The systemic effects of acromegaly, including cardiovascular, respiratory, metabolic, and neurologic complications, lead to elevated mortality in these patients, which should be managed by suppressing GH and IGF-1 levels to that of the normal population [4]. The gene discussed is GH1; the disease is acromegaly.